Lincoln Pharmaceuticals Ltd Falls to 52-Week Low of Rs 442.85

Stock Performance and Market Context

On the day the new low was recorded, Lincoln Pharmaceuticals’ share price touched an intraday low of Rs.442.85, down 2.28% from the previous close. The stock has been falling for two consecutive sessions, delivering a cumulative return of -2.57% over this period. Despite the broader market recovery, with the Sensex closing 0.35% higher at 81,820.51 after a volatile session, Lincoln Pharmaceuticals underperformed its sector by 1.01%.

The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum. This contrasts with the Sensex, which, although trading below its 50-day moving average, benefits from mega-cap leadership and a 50DMA positioned above the 200DMA, indicating a more stable medium-term trend.

Over the past year, Lincoln Pharmaceuticals has delivered a total return of -32.12%, markedly underperforming the Sensex’s 8.61% gain. The stock’s 52-week high was Rs.804.70, highlighting the extent of the decline from its peak.

Financial Performance Highlights

Lincoln Pharmaceuticals’ recent financial results have contributed to the subdued sentiment. The company reported flat results for the quarter ended September 2025, with Profit After Tax (PAT) declining by 24.1% to Rs.19.98 crores. Profit Before Tax excluding other income (PBT less OI) also fell by 12.98% to Rs.21.58 crores. These figures indicate a contraction in profitability despite stable sales.

Return on Capital Employed (ROCE) for the half-year period stood at 15.46%, the lowest recorded in recent times, while Return on Equity (ROE) was at 11.2%. Although the company maintains a low average debt-to-equity ratio of zero, signalling a conservative capital structure, the modest profitability metrics have weighed on investor confidence.

Net sales have grown at a compounded annual rate of 9.21% over the last five years, while operating profit has expanded at a slower pace of 5.37%, reflecting challenges in margin expansion. Over the past year, profits have declined by 17.2%, further underscoring the earnings pressure.

Market Position and Shareholding

Despite its size, Lincoln Pharmaceuticals has limited participation from domestic mutual funds, which hold a negligible stake in the company. Given that domestic mutual funds typically conduct thorough on-the-ground research, their minimal exposure may reflect reservations about the company’s valuation or business prospects at current price levels.

The stock’s Mojo Score stands at 37.0 with a Mojo Grade of Sell, an improvement from a previous Strong Sell rating as of 5 August 2025. The Market Cap Grade is 4, indicating a mid-tier market capitalisation relative to peers. These ratings reflect the company’s current standing within the Pharmaceuticals & Biotechnology sector, which itself has seen mixed performance amid evolving industry conditions.

Comparative Performance and Valuation

Lincoln Pharmaceuticals has underperformed not only the Sensex but also the broader BSE500 index over the last three years, one year, and three months. This sustained underperformance highlights challenges in both long-term growth and near-term earnings momentum.

Valuation metrics present a nuanced picture. The stock trades at a Price to Book Value of 1.3, which is considered fair relative to its peers’ historical averages. The company’s ROE of 11.2% suggests moderate profitability, though it has not translated into share price appreciation. The low debt levels provide financial flexibility, but have not been sufficient to offset the impact of declining profits and subdued sales growth.

Summary of Key Metrics

To summarise, Lincoln Pharmaceuticals Ltd’s stock has reached a new 52-week low of Rs.442.85 amid a backdrop of declining profitability and subdued sales growth. The company’s financial indicators show a contraction in earnings with PAT down 24.1% in the latest quarter and a ROCE at a recent low of 15.46%. The stock’s performance over the past year has been notably weaker than the benchmark Sensex, with a total return of -32.12% compared to the Sensex’s 8.61% gain.

While the company maintains a conservative capital structure with zero average debt-to-equity, its valuation metrics suggest a fair price relative to peers, with a Price to Book Value of 1.3 and an ROE of 11.2%. The limited interest from domestic mutual funds and the downgrade in Mojo Grade to Sell reflect ongoing concerns about the company’s growth trajectory and earnings stability.

Overall, the stock’s recent decline to its 52-week low underscores the challenges faced by Lincoln Pharmaceuticals in maintaining momentum within a competitive Pharmaceuticals & Biotechnology sector.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →